Evidence map›Paper›PMID 17640293›Full record

ArticleFEMS immunology and medical microbiology2007

A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.

Wen-Tssann Liu, Hui-Ling Hsu, Chung-Chih Liang, Chuan-Chang Chuang, Huang-Chi Lin, Yu-Tien Liu

Abstract readComparative Study
In one paragraph

Article in FEMS immunology and medical microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Plague Vaccines: Status and Future.Advances in experimental medicine and biology · 2016
    Review
  2. Developing live vaccines against plague.Journal of infection in developing countries · 2011
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wen-Tssann LiuInstitute of Preventive Medicine, National Defence Medical Center, Taipei, Taiwan. jeffwtliu@yahoo.com.tw
Hui-Ling Hsu
Chung-Chih Liang
Chuan-Chang Chuang
Huang-Chi Lin
Yu-Tien Liu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the relative immunogenicity and protective efficacy of recombinant X85MF1 and X85V strains of DeltacyaDeltacrpDeltaasd-attenuated Salmonella Typhimurium expressing, respectively, secreted Yersinia pestis F1 and V antigens, following intranasal (i.n.) or i.n. combined with oral immunization for a mouse model. A single i.n. dose of 10(8) CFU of X85MF1 or X85V induced appreciable serum F1- or V-specific IgG titres, although oral immunization did not. Mice i.n. immunized three times (i.n. x 3) with Salmonella achieved the most substantial F1/V-specific IgG titres, as compared with corresponding titres for an oral-primed, i.n.-boosted (twice; oral-i.n. x 2) immunization regimen. The level of V-specific IgG was significantly greater than that of F1-specific IgG (P<0.001). Analysis of the IgG antibodies subclasses revealed comparable levels of V-specific Th-2-type IgG1 and Th-1-type IgG2a, and a predominance of F1-specific Th-1-type IgG2a antibodies. In mice immunized intranasally, X85V stimulated a greater IL-10-secreting-cell response in the lungs than did X85MF1, but impaired the induction of gamma-interferon-secreting cells. A program of i.n. x 3 and/or oral-i.n. x 2 immunization with X85V provided levels of protection against a subsequent lethal challenge with Y. pestis, of, respectively, 60% and 20%, whereas 80% protection was provided following the same immunization but with X85MF1.

Indexed as

Administration, IntranasalAdministration, OralAnimalsAntibodies, BacterialAntigens, BacterialBacterial ProteinsFemaleImmunizationImmunoglobulin GMiceMice, Inbred BALB CPlaguePlague VaccinePore Forming Cytotoxic ProteinsRecombinant Fusion ProteinsSalmonella typhimuriumAntibodies, BacterialAntigens, BacterialBacterial Proteinscaf1 protein, Yersinia pestisImmunoglobulin GLcrV protein, YersiniaPlague VaccinePore Forming Cytotoxic ProteinsRecombinant Fusion ProteinsVaccines, Synthetic

Identifiers

PMID17640293
PMCPMC2121146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.